• ECS to launch AVANI AVA, a new medicinal cannabis brand tailored to women's health
• Initial range includes pessaries, capsules, topical cream and flower
• AVANI AVA strengthens ECS's differentiated B2C portfolio and supports further growth across pharmacy, prescriber and export channels

ECS Botanics Holdings Ltd (ASX:ECS), a leading medicinal cannabis company, is pleased to announce the forthcoming launch of AVANI AVA, a new range of medicinal cannabis products designed to address the specific health needs of women. Women now account for more than 40% of medicinal cannabis approvals under Australia's Special Access Scheme Category B (SAS-B), highlighting a growing demand for treatments tailored to female health conditions. ECS has developed AVANI AVA in direct response to this trend, leveraging its vertically integrated operations and formulation expertise to deliver carefully designed products across a range of delivery formats. The initial AVANI AVA range will launch in January 2026, with products formulated to support management of conditions commonly reported by women under the SAS-B program. The initial range includes pessaries, flower, topical cream, and capsules. AVANI AVA builds on the momentum of ECS's Avani-branded range and forms part of the Company's broader strategy to deliver differentiated, clinically relevant products. The Company expects AVANI AVA to enhance its position in the B2C market, deepen engagement with prescribers and pharmacists specialising in women's health and drive growth across domestic and export channels through CY2026.

ECS expects AVANI AVA to enhance its position in the B2C market, deepen engagement with prescribers and pharmacists specialising in women's health, and drive growth across domestic and export channels through CY2026.